Market research
OPL.AU Opyl Limited
AU AUD Healthcare
Latest close
As of 25 Oct 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU0000070856
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.06
About
About Opyl Limited
Pathkey.AI Ltd engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process for biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Milsons Point, Australia.
Research context
Opyl Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OPL.AU discussion.
5 years, 6 months ago
Opyl Limited is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.8.
Opyl Limited's total revenue rose by 32.9% to $487K since the same quarter in the previous year.
Its net income has increased by 102.6% to $22K since the same quarter in the previous year.
Finally, its free cash flow grew by 102.0% to $8K since the same quarter in the previous year.
Based on the above factors, Opyl Limited gets an overall score of 5/5.